<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00796328</url>
  </required_header>
  <id_info>
    <org_study_id>IWK-4462-2008</org_study_id>
    <nct_id>NCT00796328</nct_id>
  </id_info>
  <brief_title>Up-Down Determination of the ED90 of Phenylephrine for Hypotension Prophylaxis in Cesarean Delivery</brief_title>
  <official_title>Up-down Determination of the ED90 of the Initial Rate of Infusion of Phenylephrine for the Prophylaxis of Spinal Induced Hypotension in Parturients Undergoing Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IWK Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IWK Health Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine the ED90 for an infusion of phenylephrine to prevent&#xD;
      spinal induced low blood pressure in parturients presenting for an elective cesarean&#xD;
      delivery. The up-down methodology (UDM) is commonly used study method to determine the dose&#xD;
      of a drug that causes the desired effect in over 90% of the subjects to whom it given. For&#xD;
      example: the investigators want to know what is the best dose of phenylephrine (from a range&#xD;
      of commonly used doses) to prevent a drop in blood pressure during cesarean delivery ninety&#xD;
      times out of one hundred when it is given at that dose. The ED90 is the effective dose at&#xD;
      which 90% of subjects will have a &quot;positive&quot; response to a phenylephrine infusion, i.e. no&#xD;
      drop in blood pressure. The investigators hypothesize that the ED90 will be between 40 - 60&#xD;
      mcg/min.&#xD;
&#xD;
      The primary outcome measure is the ED90 for phenylephrine infusions that prevents a drop in&#xD;
      blood pressure in women undergoing cesarean delivery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Results Invalid, study closed, analysis cannot proceed.&#xD;
  </why_stopped>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effective Dose of Phenylephrine at Which 90% of Subjects Have no Spinal Induced Hypotension</measure>
    <time_frame>Spinal administration until delivery</time_frame>
    <description>The effective dose at which 90% of subjects will have a &quot;positive&quot; response to a phenylephrine infusion, i.e. no spinal induced hypotension. We hypothesize that the ED90 will be between 40 - 60 mcg/min.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Spinal Induced Hypotension in Cesarean Delivery</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine infusion</intervention_name>
    <description>Up-down, biased coin design</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Non-emergent cesarean delivery with planned spinal anesthesia (i.e. elective planned&#xD;
             cesarean delivery for malposition, patient choice, cervical pelvic disproportion,&#xD;
             previous cesarean delivery and other diagnosis that require a predetermined cesarean&#xD;
             delivery)&#xD;
&#xD;
          2. American Society of Anesthesia physical status class I &amp; II (ASA I - Healthy, ASA II -&#xD;
             mild and controlled systemic disease, eg. controlled essential hypertension)&#xD;
&#xD;
          3. Age ≥ 18 years (Standard within the obstetrical literature)&#xD;
&#xD;
          4. Term gestational age&#xD;
&#xD;
          5. English-speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Morbid Obesity (Body Mass Index ≥ 45 kg/m2) (Morbidly obese parturients require a dose&#xD;
             of local anesthetic less than the standardized dose in this study, typically have an&#xD;
             exaggerated response to vasopressors, and the blood pressure cuff occasionally needs&#xD;
             to be replaced by an intra-arterial catheter due to limitations in size)&#xD;
&#xD;
          2. Height &lt; 5'0&quot; (Women &lt; 5'0&quot; are likely to require a dose of local anesthetic less than&#xD;
             the standardized dose in this study)&#xD;
&#xD;
          3. Laboring women&#xD;
&#xD;
          4. Urgent or emergency cesarean delivery&#xD;
&#xD;
          5. Hypertensive disease of pregnancy&#xD;
&#xD;
          6. Severe maternal cardiac disease&#xD;
&#xD;
          7. Subjects on monoamine oxidase inhibitors (MAOI's) or tricyclic antidepressants&#xD;
&#xD;
          8. Fetal anomalies or intrauterine fetal death&#xD;
&#xD;
          9. Failed spinal anesthesia&#xD;
&#xD;
         10. Subject enrollment in another study involving a study medication within 30 days of CD&#xD;
&#xD;
         11. Any other physical or psychiatric condition which may impair their ability to&#xD;
             cooperate with study data collection&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>November 19, 2008</study_first_submitted>
  <study_first_submitted_qc>November 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2008</study_first_posted>
  <results_first_submitted>March 14, 2014</results_first_submitted>
  <results_first_submitted_qc>March 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 21, 2014</results_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IWK Health Centre</investigator_affiliation>
    <investigator_full_name>Ronald George</investigator_full_name>
    <investigator_title>Primary Investigator, MD, FRCPC, Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Six subjects were withdrawn from the study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phenylephrine Infusion</title>
          <description>Phenylephrine infusion : Up-down, biased coin design</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>experienced hypotension requiring tx</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phenylephrine Infusion</title>
          <description>Phenylephrine infusion : Up-down, biased coin design</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effective Dose of Phenylephrine at Which 90% of Subjects Have no Spinal Induced Hypotension</title>
        <description>The effective dose at which 90% of subjects will have a &quot;positive&quot; response to a phenylephrine infusion, i.e. no spinal induced hypotension. We hypothesize that the ED90 will be between 40 - 60 mcg/min.</description>
        <time_frame>Spinal administration until delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine Infusion</title>
            <description>Phenylephrine infusion : Up-down, biased coin design</description>
          </group>
        </group_list>
        <measure>
          <title>Effective Dose of Phenylephrine at Which 90% of Subjects Have no Spinal Induced Hypotension</title>
          <description>The effective dose at which 90% of subjects will have a &quot;positive&quot; response to a phenylephrine infusion, i.e. no spinal induced hypotension. We hypothesize that the ED90 will be between 40 - 60 mcg/min.</description>
          <units>dose of phenylephrine</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">An error in the up-down sequencing was discovered. The subsequent participants would have allocated to a dose incorrectly as per the biased coin design. The results are invalid.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Phenylephrine Infusion</title>
          <description>Phenylephrine infusion : Up-down, biased coin design</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ron George</name_or_title>
      <organization>IWK Health Centre</organization>
      <phone>470-6627</phone>
      <email>rbgeorge@dal.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

